Arginine-Rich Peptide Conjugation to Morpholino Oligomers: Effects on Antisense Activity and Specificity
Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation...
Saved in:
Published in: | Bioconjugate chemistry Vol. 16; no. 4; pp. 959 - 966 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
American Chemical Society
01-07-2005
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2−PMO generated antisense activity 3−25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2−PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2−PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations ≤10 μM, only l-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an l- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound. |
---|---|
AbstractList | Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2-PMO generated antisense activity 3-25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2-PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2-PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations less than or equal to muM, only L-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound.[PUBLICATION ABSTRACT] Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2-PMO generated antisense activity 3-25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2-PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2-PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations less than or equal to 10 mu M, only L-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound. Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2−PMO generated antisense activity 3−25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2−PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2−PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations ≤10 μM, only l-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an l- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound. Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2-PMO generated antisense activity 3-25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2-PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2-PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations < or = 10 microM, only L-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound. |
Author | Nelson, Michelle H Stein, David A Iversen, Patrick L Hatlevig, Susie A Moulton, Hong M Kroeker, Andrew D |
Author_xml | – sequence: 1 givenname: Michelle H surname: Nelson fullname: Nelson, Michelle H – sequence: 2 givenname: David A surname: Stein fullname: Stein, David A – sequence: 3 givenname: Andrew D surname: Kroeker fullname: Kroeker, Andrew D – sequence: 4 givenname: Susie A surname: Hatlevig fullname: Hatlevig, Susie A – sequence: 5 givenname: Patrick L surname: Iversen fullname: Iversen, Patrick L – sequence: 6 givenname: Hong M surname: Moulton fullname: Moulton, Hong M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16029037$$D View this record in MEDLINE/PubMed |
BookMark | eNpl0N1qFDEUB_AgFfuhF76ABEGhF6P5mMlkvNsu1QqVLm1F8CZkMme22c4m0yQj9q63vmafpJFdWtCrJJwfJ-f899GO8w4Qek3JB0oY_dgaUhFKyuoZ2qMVI0UpKdvJd1LygkrCdtF-jCtCSEMle4F2qSCsIbzeQ9ezsLTOOijOrbnCCxiT7QDPvVtNS52sdzh5_M2H8coP1nl8NtilX0OIn-7v_uDjvgeTIs5s5pKN4CLgmUn2l023WLsOX4xgbG9Nfr9Ez3s9RHi1PQ_Q98_Hl_OT4vTsy9f57LTQJWlS0fBWMF0zTYwAqI1ppWasraTo6hJKXmnBeQltTztSV33eJa8siZGUU6hEzQ_Q-03fMfibCWJSaxsNDIN24KeoaM1lyRjN8O0_cOWn4PJsilFBpRCyyehwg0zwMQbo1RjsWodbRYn6G796jD_bN9uGU7uG7klu886g2AAbE_x-rOtwrfLgdaUuFxdqfiLPf_7gC3WU_buN1yY-Dff_xw_36Zwh |
CitedBy_id | crossref_primary_10_1093_brain_awq002 crossref_primary_10_1016_j_virol_2008_03_032 crossref_primary_10_1039_C3RA45257C crossref_primary_10_1128_AAC_00644_06 crossref_primary_10_1128_AAC_01286_05 crossref_primary_10_1134_S1068162023060067 crossref_primary_10_1002_0471142727_mb2608s83 crossref_primary_10_1002_iub_297 crossref_primary_10_1021_cr0502448 crossref_primary_10_1002_0471142700_nc0430s27 crossref_primary_10_1039_C4MD00184B crossref_primary_10_1016_j_cell_2007_09_043 crossref_primary_10_1016_j_jconrel_2012_04_003 crossref_primary_10_1016_j_jconrel_2006_09_011 crossref_primary_10_1016_j_vetmic_2006_06_006 crossref_primary_10_1021_ja060873e crossref_primary_10_1016_j_tet_2008_11_069 crossref_primary_10_1038_nprot_2007_302 crossref_primary_10_31857_S013234232306009X crossref_primary_10_1128_AAC_00011_08 crossref_primary_10_1128_JVI_02360_06 crossref_primary_10_1021_acs_orglett_6b03342 crossref_primary_10_1039_c3ra47841f crossref_primary_10_1007_s00204_021_03184_z crossref_primary_10_1128_AAC_50_3_984_993_2006 crossref_primary_10_1002_med_21706 crossref_primary_10_3390_polym9050177 crossref_primary_10_1016_j_addr_2015_02_008 crossref_primary_10_3390_molecules14031304 crossref_primary_10_1007_s00705_008_0067_0 crossref_primary_10_1038_nrd3459 crossref_primary_10_1093_jac_dkn221 crossref_primary_10_1016_j_antiviral_2011_04_012 crossref_primary_10_1128_JVI_00557_07 crossref_primary_10_1111_j_1440_1681_2006_04403_x crossref_primary_10_3390_molecules29112658 crossref_primary_10_1007_s00249_023_01673_w crossref_primary_10_1002_cpnc_21 crossref_primary_10_1038_onc_2011_300 crossref_primary_10_1128_AAC_00936_08 crossref_primary_10_1128_JVI_00900_06 crossref_primary_10_1089_nat_2013_0449 crossref_primary_10_1016_j_antiviral_2006_05_017 crossref_primary_10_1016_j_medidd_2023_100166 crossref_primary_10_3390_ph3030448 crossref_primary_10_1016_j_tetlet_2008_04_035 |
Cites_doi | 10.1128/JVI.78.11.5891-5899.2004 10.1021/jm0105676 10.1021/bc034221g 10.1128/JVI.79.8.5116-5128.2005 10.1016/j.addr.2004.10.003 10.1089/108729003764097322 |
ContentType | Journal Article |
Copyright | Copyright © 2005 American Chemical Society Copyright American Chemical Society Jul/Aug 2005 |
Copyright_xml | – notice: Copyright © 2005 American Chemical Society – notice: Copyright American Chemical Society Jul/Aug 2005 |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7TM 8FD FR3 P64 |
DOI | 10.1021/bc0501045 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Nucleic Acids Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Nucleic Acids Abstracts Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | Engineering Research Database Engineering Research Database MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry Biology |
EISSN | 1520-4812 |
EndPage | 966 |
ExternalDocumentID | 878012731 10_1021_bc0501045 16029037 ark_67375_TPS_CH8RZW3P_B b317947587 |
Genre | Journal Article Feature |
GroupedDBID | - 23N 53G 55A 5GY 5VS 7~N AABXI ABMVS ABUCX ACGFS ACIWK ACJ ACPRK ACS AEESW AENEX AFEFF AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS ANTXH AQSVZ CS3 DU5 EBS ED ED~ EJD F5P GNL IH9 IHE JG JG~ LG6 P2P PQEST PQQKQ ROL TN5 TWZ UI2 VF5 VG9 W1F X XKZ YZZ --- -~X 4.4 ABJNI ABQRX ADHLV AGXLV AHGAQ BAANH BSCLL CUPRZ GGK 1WB AALRI AAXUO ABHMW CGR CUY CVF ECM EIF FDB NPM RNS AAYXX CITATION 7QO 7TM 8FD FR3 P64 |
ID | FETCH-LOGICAL-a409t-93b62a72a0c6ee7ccb8a22b586d74e435a6334ebf1d075f16052080c8131e5673 |
IEDL.DBID | ACS |
ISSN | 1043-1802 |
IngestDate | Thu Aug 15 22:30:32 EDT 2024 Thu Oct 10 16:55:38 EDT 2024 Fri Aug 23 00:39:08 EDT 2024 Sat Sep 28 07:45:22 EDT 2024 Wed Oct 30 09:29:41 EDT 2024 Thu Aug 27 13:42:48 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a409t-93b62a72a0c6ee7ccb8a22b586d74e435a6334ebf1d075f16052080c8131e5673 |
Notes | ark:/67375/TPS-CH8RZW3P-B istex:05984FB69C031BA5593673E167788B56AD34B3F0 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 16029037 |
PQID | 216186689 |
PQPubID | 45565 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_17384221 proquest_journals_216186689 crossref_primary_10_1021_bc0501045 pubmed_primary_16029037 istex_primary_ark_67375_TPS_CH8RZW3P_B acs_journals_10_1021_bc0501045 |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 XKZ 7~N ACJ VG9 W1F ANTXH ACS AEESW AFEFF ABMVS ABUCX IH9 AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 2005-07-01 |
PublicationDateYYYYMMDD | 2005-07-01 |
PublicationDate_xml | – month: 07 year: 2005 text: 2005-07-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | Bioconjugate chemistry |
PublicationTitleAlternate | Bioconjugate Chem |
PublicationYear | 2005 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | Stein D. (bc0501045b00015/bc0501045b00015_1) 1997 Arora V. (bc0501045b00004/bc0501045b00004_1) 2002; 91 Summerton J. E. (bc0501045b00005/bc0501045b00005_1) 2003 Neuman B. W. (bc0501045b00010/bc0501045b00010_1) 2005 Kinney R. M. (bc0501045b00012/bc0501045b00012_1) 2005; 79 Summerton J. (bc0501045b00001/bc0501045b00001_1) 1997 Rothbard J. B. (bc0501045b00017/bc0501045b00017_1) 2002; 45 bc0501045b00008/bc0501045b00008_1 Rothbard J. B. (bc0501045b00018/bc0501045b00018_1) 2005; 57 Summerton J. (bc0501045b00002/bc0501045b00002_1) 1999; 1489 Hudziak R. M. (bc0501045b00003/bc0501045b00003_1) 1996 Moulton H. M. (bc0501045b00007/bc0501045b00007_1) 2003; 13 Kang S. H. (bc0501045b00014/bc0501045b00014_1) 1998 Deas T. S. (bc0501045b00011/bc0501045b00011_1) 2005; 79 Corey D. R. (bc0501045b00016/bc0501045b00016_1) 1995; 117 Neuman B. W. (bc0501045b00009/bc0501045b00009_1) 2004; 78 Ghosh C. (bc0501045b00006/bc0501045b00006_1) 2000 Summerton J. (bc0501045b00013/bc0501045b00013_1) 1991 |
References_xml | – volume-title: Uncharged morpholino-based polymers having phosphorus containing chiral intersubunit linkages. U.S. Patent 5185444 year: 1991 ident: bc0501045b00013/bc0501045b00013_1 contributor: fullname: Summerton J. – volume: 117 year: 1995 ident: bc0501045b00016/bc0501045b00016_1 publication-title: J. Am. Chem. Soc. contributor: fullname: Corey D. R. – year: 2005 ident: bc0501045b00010/bc0501045b00010_1 publication-title: J. Virol., in press. contributor: fullname: Neuman B. W. – volume-title: Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules year: 2003 ident: bc0501045b00005/bc0501045b00005_1 contributor: fullname: Summerton J. E. – volume: 78 year: 2004 ident: bc0501045b00009/bc0501045b00009_1 publication-title: J. Virol. doi: 10.1128/JVI.78.11.5891-5899.2004 contributor: fullname: Neuman B. W. – volume: 45 year: 2002 ident: bc0501045b00017/bc0501045b00017_1 publication-title: J. Med. Chem. doi: 10.1021/jm0105676 contributor: fullname: Rothbard J. B. – volume-title: Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187−195 year: 1997 ident: bc0501045b00001/bc0501045b00001_1 contributor: fullname: Summerton J. – ident: bc0501045b00008/bc0501045b00008_1 doi: 10.1021/bc034221g – volume: 79 year: 2005 ident: bc0501045b00012/bc0501045b00012_1 publication-title: J. Virol. doi: 10.1128/JVI.79.8.5116-5128.2005 contributor: fullname: Kinney R. M. – volume: 91 year: 2002 ident: bc0501045b00004/bc0501045b00004_1 publication-title: J. Pharm. Sci. contributor: fullname: Arora V. – volume: 57 year: 2005 ident: bc0501045b00018/bc0501045b00018_1 publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2004.10.003 contributor: fullname: Rothbard J. B. – volume-title: DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7, 151−157. year: 1997 ident: bc0501045b00015/bc0501045b00015_1 contributor: fullname: Stein D. – volume-title: Evaluation of antisense mechanisms of action. Methods Enzymol. 313, 135−143 year: 2000 ident: bc0501045b00006/bc0501045b00006_1 contributor: fullname: Ghosh C. – volume: 1489 year: 1999 ident: bc0501045b00002/bc0501045b00002_1 publication-title: Biochim. Biophys. Acta contributor: fullname: Summerton J. – volume: 79 year: 2005 ident: bc0501045b00011/bc0501045b00011_1 publication-title: J. Virol. contributor: fullname: Deas T. S. – volume-title: Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37, 6235−6239 year: 1998 ident: bc0501045b00014/bc0501045b00014_1 contributor: fullname: Kang S. H. – volume: 13 start-page: 43 year: 2003 ident: bc0501045b00007/bc0501045b00007_1 publication-title: Antisense Nucleic Acid Drug Dev. doi: 10.1089/108729003764097322 contributor: fullname: Moulton H. M. – volume-title: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267−272 year: 1996 ident: bc0501045b00003/bc0501045b00003_1 contributor: fullname: Hudziak R. M. |
SSID | ssj0009182 |
Score | 2.087131 |
Snippet | Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective... |
SourceID | proquest crossref pubmed istex acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 959 |
SubjectTerms | Amino acids Arginine - chemistry Base Sequence DNA Primers Enzyme Stability HeLa Cells Humans Morpholines - chemistry Oligonucleotides, Antisense - chemistry Oligonucleotides, Antisense - pharmacology Peptides Peptides - chemistry Polymers Ribonucleic acid RNA |
Title | Arginine-Rich Peptide Conjugation to Morpholino Oligomers: Effects on Antisense Activity and Specificity |
URI | http://dx.doi.org/10.1021/bc0501045 https://api.istex.fr/ark:/67375/TPS-CH8RZW3P-B/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/16029037 https://www.proquest.com/docview/216186689 https://search.proquest.com/docview/17384221 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB7RVgguUFoeoVAsQL1FxE78CLc0tNoLsGKLQFwi23FWUEjQZleiN678TX4JHmcfQlDBLVIcxZnP0Yxnxt8H8FQnQlOWuLhOMVtldB4bWqO-ibS24Y4biwm30US-eq9enCBNzpNLKviMPjM24bhp4Fuww6SPEDD-KScbZl2qhpImcm0qbNfZ_eNRdD22_8317KAVv10eVwb_cnrzv2a2CzeW4SMpBrxvwRXX7sF-0fqt85cLckRCQ2fIlO_B1ePV1bVyJeu2D-fFbIqiEC7GM_VkjF0ttSNl135aTANMZN6Rl523P-r5dOT154_TDrPbz39-_0EGtuOe-GFFi0LObe9IYQcNCqLbmgRFe-SlmF_chrenJ2flKF4qLsTa7_PmcZ4awbRkOrHCOY-WUZoxw5WoZeZ8ZKVFmmbONB5OyRsqsItGJVbRlDouZHoHttuudfeA1DKh3v8qvxR8kMYbk9EmU7XKcqsMzUwEhx6SavnH9FUohjNarY0aweMVWtXXgXnjb4OOAo7rEXp2jq1qkldn40lVjtSbD-_ScXUcwcEK6M07WVALECqP4NH6rocDaya6dd3CT0umKmOMRnB3WB2buYiE5Ukq7__rQw7geuB7DT2-D2B7Plu4h7DV14vDsJJ_Aecp6Mk |
link.rule.ids | 315,782,786,2769,27085,27933,27934,56747,56797 |
linkProvider | American Chemical Society |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB3RVqhcoLR8hEJrIdRbROwkjsMtDa0W0ZYVuwjEJbIdZwUFB212JXrjyt_kl-Bx9kMIEOIWKU4y8XM045nJewBPZMQlZZEJ6xizVUrmoaI16ptkWjepSZXGhNtglF28E89PVjQ5-C-MM6Jzd-p8EX_NLkCfKh2luHdIN2Ar5S4IxjCoHK0JdqnoK5tIuSmwa2fnt0vRA-nuFw-0hZP59e_hpXczp7f-x8AduLkIJknRo38brhm7C3uFdRvpz1fkiPj2Tp8334Xrx8uj7XIp8rYHl8V0ghIRJsQ_7MkQe1xqQ8rWfpxPPGhk1pLz1qGB6j4tefXpw6TFXPezH9--k577uCNuWGFR1tl2hhS6V6Qg0tbE69sjS8Xs6g68OT0Zl4Nwob8QSrfrm4V5rDiTGZOR5sY47JSQjKlU8DpLjIuzJI_jxKjGgZulDeXYUyMiLWhMjcMovgubtrXmPpA6i6jzxsItDBeypY1KaJOIWiS5FoomKoADN6fV4vvpKl8aZ7RaTWoAj5egVV96Ho4_DTrycK5GyOklNq5laTUejqpyIF6_fxsPq-MA9pd4r5_JvHYAF3kAh6uzDg6soEhr2rkzK4tFwhgN4F6_SNa28IjlUZw9-NeLHML2YHx-Vp29uHi5Dzc8E6zv_n0Im7Pp3DyCja6eH_jF_RPGTPE2 |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RVjwuUFoeodBaCPUWiJ2HHW5p2tUioKzYIioukR07q7aQVJtdid648jf5JXicza4QIMQtUpzE8TfWPD0fwDMZJJKywPg6xGiVkqmvqEZ-E16WVWxiVWLAbTjmx6fi8Ajb5Dzvz8LYSbT2Ta1L4uOuvtTVosMAfaHKIEb_IV6DjTjhKTpbWT5eNdmlostuYttNgZU7m789ilqobH_RQhu4oF__bmI6VTO487-T3ITbC6OSZJ0U3IVrpt6C7ay2DvWXK7JPXJmni59vwfWD_upm3pO9bcNFNp0gVYTx8aQ9GWGtizYkb-rz-cSBR2YNedtYVJDlpyHvPp9NGox5v_zx7TvpeiC3xA7LaqR3rltDsrJjpiCy1sTx3GO3itnVPfgwODrJh_6Ch8GX1vub-WmoEiY5k0GZGGMxVEIypmKRaB4Za2_JJAwjoyoLMo8rmmBtjQhKQUNqLE7hfVivm9o8BKJ5QK1WFlZArOkWVyqiVSS0iNJSKBopD3btuhaLfdQWLkXOaLFcVA-e9sAVl10_jj8N2neQLkfI6QUWsPG4OBmNi3wo3n_6GI6KAw92esxX32SOQyARqQd7y7sWDsykyNo0czstHoqIMerBg05QVnNJApYGIX_0rx_Zgxujw0Hx5tXx6x245RrCuiLgx7A-m87NE1hr9XzXyfdPyb3zuQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Arginine-Rich+Peptide+Conjugation+to+Morpholino+Oligomers%3A+Effects+on+Antisense+Activity+and+Specificity&rft.jtitle=Bioconjugate+chemistry&rft.au=Nelson%2C+Michelle+H&rft.au=Stein%2C+David+A&rft.au=Kroeker%2C+Andrew+D&rft.au=Hatlevig%2C+Susie+A&rft.date=2005-07-01&rft.pub=American+Chemical+Society&rft.issn=1043-1802&rft.eissn=1520-4812&rft.volume=16&rft.issue=4&rft.spage=959&rft_id=info:doi/10.1021%2Fbc0501045&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=878012731 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-1802&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-1802&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-1802&client=summon |